A5003336040- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Lung Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- PARP inhibition in cancer therapy
- RNA modifications and cancer
- Colorectal and Anal Carcinomas
- Breast Cancer Treatment Studies
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Molecular Biology Techniques and Applications
- Cancer Treatment and Pharmacology
- Colorectal Cancer Screening and Detection
- Mycobacterium research and diagnosis
- Cancer Mechanisms and Therapy
- Diagnosis and treatment of tuberculosis
- Protein Tyrosine Phosphatases
Guardant (United States)
2018-2025
Rabin Medical Center
2018
This study examined the impact of Recurrence Score (RS) in Spanish breast cancer patients and explored associations between clinicopathological markers likelihood change treatment recommendations.
Abstract The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating DNA sequencing to interrogate the genomic profile ABC in 800 patients plasmaMATCH trial. We demonstrate diverse subclonal resistance mutations, including enrichment HER2 mutations positive disease, co-occurring ESR1 MAP kinase pathway HR + HER2− disease that associate...
Total neoadjuvant treatment (TNT) is a valid strategy for patients with high-risk locally advanced rectal cancer (LARC). Biomarkers of response to TNT are an unmet clinical need. We aimed determine the value circulating tumor DNA (ctDNA) predict response, recurrence, and survival in LARC treated TNT.The GEMCAD 1402 was phase II randomized, multicentric trial that randomized 180 modified schedule fluorouracil, leucovorin, oxaliplatin (mFOLFOX6) +/- aflibercept, followed by chemoradiation...
Detection of circulating tumor DNA (ctDNA) is a minimally invasive and convenient blood-based screening strategy that may increase effectiveness colorectal cancer (CRC) screening.A novel multimodal ctDNA-based blood assay integrates genomics, epigenomics fragmentomics, as well proteomics in refined version, was tested samples from two cohorts: (i) consecutive fecal immunochemical test (FIT)-positive individuals the CRC Barcelona stool-based program; (ii) patients diagnosed with CRC. Primary...
BRAF V600 mutations have been found in 1–2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment dabrafenib plus trametinib progression free survival (PFS) 10.9 months. However, 50–80% are non-V600, can be class II, intermediate to high kinase activity RAS independence, or III, impaired activity, upstream signaling dependence, consequently, sensitivity receptor tyrosine (RTK) inhibitors. Plasma cell-free DNA (cfDNA) 185 newly diagnosed...
Treatment guidelines for advanced non-small-cell lung cancer (aNSCLC) recommend broad molecular profiling targeted therapy selection. This study prospectively assessed comprehensive next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA) compared with standard-of-care (SOC) tissue-based testing to identify guideline-recommended alterations in aNSCLC.Patients treatment-naïve aNSCLC were tested using a well-validated NGS cfDNA panel, and results SOC tissue testing. The...
Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation (NGS) standard but tissue quantity, quality, and time-to-results remains problematic. Here, we compare upfront cell-free-DNA (cfDNA) NGS clinical utility against routine testing in patients with aNSCLC.cfDNA-NGS was performed consecutive, newly identified aNSCLC between December 2019-October 2021 alongside genotyping. Variants were interpreted using...
•Complete genotyping in mCRC is essential the selection of optimal therapy first line.•Adoption ctDNA testing into clinical practice has potential to improve care patients with mCRC.•Testing can identify biomarkers a significantly shorter TAT than SOC tissue.•Use validated, high-sensitivity comprehensive allows fully informed treatment decisions be made earlier.•Implementing ahead tissue time initiation without compromising biomarker discovery. BackgroundComprehensive selecting for...
Abstract Background: The investigator-initiated, prospective, single-arm CALIBRATION trial (NCT03653052) was designed to evaluate early (weeks 4 and 7) liquid biopsies for concordance with meaningful treatment response (week 26) in patients advanced esophageal cancer. Participants were given durvalumab (a PD-L1 inhibitor) following at least one prior systemic therapy. Methods: received 1500 mg of every four weeks. Circulating tumor DNA (ctDNA) analyzed Guardant 360® CDx baseline, week 4, 7....
Abstract Circulating tumor DNA (ctDNA) levels may predict response to anticancer drugs, including CDK4/6 inhibitors and endocrine therapy combinations (CDK4/6i+ET); however, critical questions remain unanswered such as which assay or statistical method use. Here, we obtained paired plasma samples at baseline week 4 in 45 consecutive patients with advanced breast cancer treated CDK4/6i+ET. ctDNA was detected 96% of cases using the 74-gene Guardant360 assay. A variant allele fraction ratio...
Background and objectiveWith European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer ongoing trials hormone-sensitive cancer, detection genetic alterations BRCA1/2 other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility comparability comprehensive next-generation sequencing (NGS) liquid biopsy (LB; circulating tumor DNA) tissue (TT) samples a real-world clinical setting.MethodsThe...
Abstract Background Tumor molecular screening allows categorization of alterations to select the best therapeutic strategy. AT-rich interactive domain-containing 1A ( ARID1A ) gene mutations are present in gastric, endometrial, and clear cell ovarian tumors. Inactivation this impairs mismatch repair (MMR) machinery leading an increased mutation burden that correlates with microsatellite instability (MSI), associated tumor-infiltrating lymphocytes programmed death ligand 1 (PD-L1) expression....
10569 Background: Preliminary data has highlighted inherited predisposition to lung cancer (LC) related certain pathogenic germline variant (PGV) in predisposing genes, including patients (pts) with tumors harboring somatic driver oncogene alterations (alt); however, the frequency of PGV LC is unknown. Liquid biopsy assays may be able identify incidental (iPGV) pts solid at scale. Here, we report prevalence iPGV genes advanced non-small cell (aNSCLC) relative alt status. Methods: Genomic...
Abstract Background: Early changes in ctDNA levels, dynamics, may help identify which patients are responding to therapy earlier than imaging. Few studies have assessed dynamics during PARP inhibitor therapy. Here we report paired baseline and early on treatment analysis from cohort E of plasmaMATCH, that recruited with TNBC olaparib (PARP inhibitor) plus ceralasertib (ATR inhibitor). Methods: The plasmaMATCH trial the ability testing allocate mutation matched cohorts (A-D). Patients TNBC,...
Abstract Background Accurate molecular profiling is crucial for optimal treatment decisions in advanced or metastatic breast cancer. Liquid biopsies, such as circulating cell-free tumor DNA (cfDNA, cftDNA ctDNA), provide a non-invasive approach to monitor alterations the tumor. The German PRAEGNANT registry study aims investigate biomarkers precision medicine and their practical integration into clinical practice. In this context, testing was performed part of research subproject, with...
<title>Abstract</title> The prospective, single-arm CALIBRATION trial (NCT03653052) assessed liquid biopsies for early response concordance compared with CT scan assessment in patients advanced oesophageal cancer given durvalumab (PD-L1 inhibitor) after at least one prior systemic therapy. 19 participants received 1500mg of every four weeks. ctDNA was analysed retrospectively Guardant 360<sup>®</sup> CDx baseline, weeks 4 and 7. Response week 26 by RECIST v1.1. Tumour samples underwent 30X...
Abstract Background Circulating cell-free tumor DNA (ctDNA) provides a non-invasive approach for assessing somatic alterations. The German PRAEGNANT registry study aims to explore molecular biomarkers and investigate their integration into clinical practice. In this context, ctDNA testing was included understand the motivations of clinicians initiate testing, identify alterations, assess impact results obtained. Methods Patients with advanced/metastatic breast cancer were prospectively...
Abstract Background: Early changes in circulating tumour DNA (ctDNA) levels may identify which patients respond to therapy earlier than imaging, with ctDNA falling rapidly who therapy. The plasmaMATCH trial assessed the utility of testing an error-corrected 73-gene targeted panel (Guardant360, Guardant Health) allocate four mutation matched cohorts. ESR1-extended fulvestrant (A), HER2-neratinib +/- (B), AKT1-capivasertib + (C), AKT basket-capivasertib (D). Here, we report paired baseline and...
Background: Next-generation sequencing (NGS) of cell-free tumor DNA (ctDNA) has great potential for liquid biopsy in cancer diagnostics and to identify patients with actionable genomic alteration. This study, a prospective longitudinal focused cohort metastatic without standard effective active antineoplastic medical treatment options establish the rate alteration accessing treatment. The final objective was determine clinical performance based on non-invasive sequencing. Methods: We...